ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.689,33
0,75%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Dr Reddys Laboratories Ltd (RDY)

  7. Dr Reddys Laboratories Ltd (RDY) News

RDY

Dr Reddys Laboratories (RDY)

Dr Reddys Laboratories Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:RDY
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202415h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
14/06/202412h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
13/06/202412h18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
12/06/202423h05Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:RDYDr Reddys Laboratories Ltd
12/06/202419h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
10/06/202412h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
07/06/202420h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
07/06/202416h39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
05/06/202414h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
04/06/202414h23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
03/06/202423h22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
03/06/202419h05Business WireAurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing CapabilitiesNYSE:RDYDr Reddys Laboratories Ltd
03/06/202412h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
31/05/202413h27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
30/05/202417h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
30/05/202417h17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
29/05/202412h18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
28/05/202415h53Business WireDr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North AmericaNYSE:RDYDr Reddys Laboratories Ltd
28/05/202413h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
24/05/202419h58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
24/05/202419h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
22/05/202419h23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
21/05/202416h59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
21/05/202416h49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
21/05/202416h05Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNYSE:RDYDr Reddys Laboratories Ltd
21/05/202414h00GlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNYSE:RDYDr Reddys Laboratories Ltd
17/05/202415h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
15/05/202420h36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
13/05/202421h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
13/05/202412h33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
 Showing the most relevant articles for your search:NYSE:RDY

Kürzlich von Ihnen besucht

BIT
UB48G0
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten